Marinus Pharmaceuticals (MRNS) Stock Price
Marinus Pharmaceuticals Price
Revenue has compounded at 68.5% per year over the past 11 years to 30.99 M USD. Marinus Pharmaceuticals's net margin stands at -456.3%, up from -1,408.5% several years earlier. Analysts set a median price target of 0.79 USD, implying 43.7% above the current price. Of 13 analysts, 6 rate the stock a buy — an overall Hold consensus.
Marinus Pharmaceuticals stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Marinus Pharmaceuticals business model & stock analysis
Frequently asked questions about Marinus Pharmaceuticals
The business model of Marinus Pharmaceuticals Inc. revolves around the development and commercialization of innovative therapeutics for neurological disorders. The company focuses on creating novel medications that target the modulation of specific neurotransmitter systems. Marinus Pharmaceuticals Inc. conducts extensive research and clinical trials to evaluate the efficacy and safety of their potential drug candidates. By leveraging their expertise in neuroscience and drug discovery, the company aims to improve the lives of patients suffering from various neurological conditions. Marinus Pharmaceuticals Inc. strives to bring innovative treatments to market, addressing unmet medical needs and creating value for shareholders.
Marinus Pharmaceuticals Inc is primarily active in the pharmaceutical industry.
Marinus Pharmaceuticals Inc faces competition from several key players in the market. Some of its main competitors include companies such as GW Pharmaceuticals, Zogenix Inc, and Sage Therapeutics. These companies operate within the pharmaceutical industry and develop products targeting similar therapeutic areas.
Marinus Pharmaceuticals Inc is a biopharmaceutical company specializing in the development of innovative therapeutics for epilepsy and neuropsychiatric disorders. Founded in 2003, the company is headquartered in Radnor, Pennsylvania. Marinus focuses on the advancement of its proprietary therapeutic platform which targets GABA receptors in the brain, aiming to offer solutions for unmet medical needs in epilepsy, postpartum depression, and other conditions. With a strong commitment to research and development, Marinus Pharmaceuticals has conducted extensive clinical trials to evaluate the efficacy and safety of its drug candidates. The company continues to strive towards improving the lives of patients and making significant contributions to the field of neuroscience.
Marinus Pharmaceuticals Inc has achieved significant milestones in its journey. Some notable accomplishments include the FDA approval of its drug, Ganaxolone, for the treatment of seizures in patients with CDKL5 deficiency disorder and PCDH19-related epilepsy. Additionally, the company has made great progress in clinical trials, demonstrating positive results in the treatment of postpartum depression and refractory status epilepticus. Marinus Pharmaceuticals has also expanded its pipeline, exploring the potential of Ganaxolone in various neurological and psychiatric conditions. With these remarkable achievements, Marinus Pharmaceuticals Inc continues to solidify its position as a leading innovator in the field of pharmaceuticals.
Marinus Pharmaceuticals Inc primarily operates in the United States.
Marinus Pharmaceuticals Inc represents values of innovation, patient-centricity, and scientific excellence. The company is dedicated to developing innovative therapies to improve the lives of patients suffering from neurological conditions. Marinus Pharmaceuticals Inc follows a corporate philosophy focused on advancing breakthrough treatments through rigorous research, clinical trials, and collaboration with healthcare professionals. With a strong commitment to patient care, Marinus Pharmaceuticals Inc aims to address unmet medical needs and deliver effective treatments that can make a meaningful difference in the lives of individuals with neurological disorders.
Analysts currently set an average price target of 1.09 USD for the Marinus Pharmaceuticals stock (median: 0.79 USD), implying +97.8 % versus the latest price. The consensus is based on 13 analyst ratings.
13 analysts currently rate the Marinus Pharmaceuticals stock: 6 recommend buying, 7 holding and 0 selling. For 2026, analysts expect Marinus Pharmaceuticals to generate revenue of 61.31 M USD and earnings per share of -0.20 USD.
Converted at the current exchange rate, the Marinus Pharmaceuticals share trades at 0.49 EUR (0.55 USD).
The Marinus Pharmaceuticals share (MRNS) is listed on 3 stock exchanges, including: NASDAQ (MRNS), London (0JYL.L), Frankfurt (61Y.F).
Marinus Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for the treatment of central nervous system disorders. The company is based in New Jersey, USA. The company's business model is centered around offering new therapeutic solutions for patients with severe neurological disorders. Its research and development efforts primarily focus on the effects of neurosteroids in alleviating symptoms of conditions such as epilepsy, depression, and schizophrenia. Marinus Pharmaceuticals currently offers two products: Ganaxolone and IV Ganaxolone, both of which are allosteric modulators of the GABAA receptor. These products have shown potential in treating conditions such as premenstrual dysphoric disorder and severe epileptic seizures, with clinical studies yielding promising results. The company collaborates with leading institutions and experts in epilepsy research and aims to expand its research and development activities in various areas of neurology to provide innovative solutions for patients with severe neurological disorders. The company maintains a strict approach to developing therapeutics and is committed to conducting thorough clinical research to ensure product safety and efficacy.
The expected revenue of Marinus Pharmaceuticals is 61.31 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Marinus Pharmaceuticals is -11.49 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Marinus Pharmaceuticals is currently -2.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Marinus Pharmaceuticals stock.
The price-to-sales ratio (P/S) of Marinus Pharmaceuticals is currently 0.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Marinus Pharmaceuticals stock.
The Eulerpool Quality Score for Marinus Pharmaceuticals is 6/10.
The ISIN of Marinus Pharmaceuticals is US56854Q2003. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Marinus Pharmaceuticals is A2QEUC. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Marinus Pharmaceuticals is MRNS. The ticker symbol is used to trade Marinus Pharmaceuticals shares on the stock exchange.
Marinus Pharmaceuticals stock
Marinus Pharmaceuticals Peer Group
Marinus Pharmaceuticals Ticker
Marinus Pharmaceuticals FIGI
All fundamentals and in-depth analysis of Marinus Pharmaceuticals
Our stock analysis for Marinus Pharmaceuticals stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Marinus Pharmaceuticals. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.